X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funding will be used to support development of RTx-021, an optogenetic therapy for the treatment of geographic atrophy (GA), the advanced form of age-related macular degeneration (AMD).
Lead Product(s): RTx-021
Therapeutic Area: Ophthalmology Product Name: RTx-021
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: CIRM
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Funding November 13, 2023
Details:
Under the agreement, Adverum grants Ray Therapeutics a worldwide, non-exclusive license of AAV.7m8 together with its RTx-015 asset, for the prevention, treatment, diagnosis or amelioration of any ocular disorder utilizing Ray’s optogenetics approach.
Lead Product(s): RTx-015,AAV.7m8
Therapeutic Area: Genetic Disease Product Name: RTx-015
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Recipient: Adverum Biotechnologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 12, 2023
Details:
The financing will advance Ray Therapeutics’ optogenetics gene therapy programs for blinding retinal diseases including, RTx-015, a genotype agnostic, intended for use in treating patients with retinitis pigmentosa (RP).
Lead Product(s): RTx-015
Therapeutic Area: Genetic Disease Product Name: RTx-015
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Novo Holdings A/S
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing May 16, 2023
Details:
Forge will provide research-grade and GMP-Pathway plasmid manufacturing services, in addition to adeno-associated viral vector (AAV) process development, scale-up engineering, and cGMP manufacturing services for Ray Therapeutics’ program, RTx-015.
Lead Product(s): RTx-015
Therapeutic Area: Genetic Disease Product Name: RTx-015
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Forge Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 10, 2022
Details:
Funding will advance development of Ray Therapeutics’ optogenetics technology platform – Ray-001 for the treatment of Retinitis Pigmentosa. In preclinical studies, RAY-001 is intended to be a one-time treatment via intravitreal injection that is sustainable for a lifetime.
Lead Product(s): Ray-001
Therapeutic Area: Genetic Disease Product Name: Ray-001
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: California Institute for Regenerative Medicine
Deal Size: $4.0 million Upfront Cash: Undisclosed
Deal Type: Funding April 26, 2022
Details:
Ray-001 is intended for use in treating patients with retinitis pigmentosa (RP). Optogenetics is a promising approach that has the potential to restore useful vision to visually-impaired and blind individuals.
Lead Product(s): Ray-001
Therapeutic Area: Genetic Disease Product Name: Ray-001
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Forge Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 01, 2022
Details:
The funding will be used to advance its optogenetic therapy, Ray-001, into clinical trials in retinitis pigmentosa (RP). Based on the durability of treatment demonstrated in preclinical studies, Ray-001 is intended to be a one-time treatment via intravitreal injection.
Lead Product(s): Ray-001
Therapeutic Area: Genetic Disease Product Name: Ray-001
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: 4BIO Capital
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Financing January 04, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
